New Mesothelioma Test - Showing Effectiveness in patients with pleural mesothelioma

New Mesothelioma Test - Showing Effectiveness in patients with pleural mesothelioma

 

Mesothelioma is an asbestos-related cancer caused by exposure to asbestos over a long period of time.Symptoms of mesothelioma may not appear for decades after initial exposure to asbestos. Therefore, usually not detected until the later stages following serious side effects begin to show themselves.What are some of the diagnosis of pleural mesothelioma? Mesothelioma is generally very difficult to diagnose because symptoms do not appear long after the initial exposure to asbestos occurs. And in most cases of pleural mesothelioma is often confused with the flu or pneumonia or other more common diseases so it is very difficult to diagnose and treat.What are the symptoms of pleural mesothelioma? Symptoms of pleural mesothelioma are very non-specific which makes it very difficult to diagnose at an early stage and treated appropriately. Other symptoms may not appear for decades after exposure to asbestos. Some of the symptoms include: * Abdominal swelling * Anemia * Acute pain in the abdominal region and chest * Coughing up blood * Difficulty swallowing * Fatigue * cough * lossWhat persistent dry weight is this new gene test a new relationship Shortness of breath? test to help predict which patients with pleural mesothelioma will benefit from multiple treatment modalities and the surgical procedure was developed by researchers at Brigham and Women's Hospital in Boston, Massachusetts. This test has proven effective in predicting postoperative outcome in pleural mesothelioma patients - this is indeed a very important advance in the diagnosis and treatment of mesothelioma.How is this test used the gene ratio test was used to analyze the relative expression levels of the four? genes involved in malignant mesothelioma. The researchers believed that there was a need to develop a molecular test that could predict the surgical outcome due to lack of current means of assessing prognosis to determine which patient will benefit mesothelioma surgery trimodal therapy.How effective is this test? According to the researchers trimodality treatment including chemotherapy and radiation with surgical resection leads to longer life expectancy than nonsurgical treatment in patients with malignant pleural mesothelioma. Although this treatment is effective in longer survival rate is only beneficial to about 50 percent of patients with malignant pleural mesothelioma which means that the other 50 percent of patients can not benefit from this test. In general, this test is a powerful new development to determine which patients will see an improvement prognosis.What mesothelioma is the survival rate of this test? The survival rate for patients who received trimodality therapy is currently about one to two years. However, approximately 20 percent of patients survive for three to fifteen years.This significant increase in survival is certainly good news for patients who may be genetically more susceptible to the benefits of this new and aggressive treatment approach.Due positive result of this test, researchers are pushing for this test to become standard practice in the diagnosis and treatment planning for pleural mesothelioma patients.How reliable is this test? The researchers said the test shows that it can be performed on samples obtained in a minimally invasive biopsy performed before major surgery. The test also indicates that can be used as a reliable source to help inform clinical decision of whether to perform major surgery or trimodal therapies besides accurately predict postoperative outcome.The new developments in drugs and treatment for mesothelioma pleural like this give hope to those suffering from mesothelioma and their loved ones.